An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 208036
Company: BRACCO

Products on NDA 208036

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
E-Z-CAT DRY	BARIUM SULFATE	40%	FOR SUSPENSION;ORAL	Discontinued	None	Yes	No
E-Z-HD	BARIUM SULFATE	98%	FOR SUSPENSION;ORAL	Prescription	None	Yes	Yes
E-Z-PAQUE	BARIUM SULFATE	96%	FOR SUSPENSION;ORAL	Prescription	None	Yes	Yes
VARIBAR THIN LIQUID	BARIUM SULFATE	81%	FOR SUSPENSION;ORAL	Prescription	None	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 208036

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
01/11/2016	ORIG-1	Approval	Type 7 - Drug Already Marketed without Approved NDA	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208036s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208036Orig1s000Approvedt.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208036Orig1s000TOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/30/2019	SUPPL-10	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208036s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/208036Orig1s010ltr.pdf
02/08/2017	SUPPL-6	Labeling-Package Insert, Labeling-Container/Carton Labels	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208036Orig1s006ltr.pdf
04/07/2017	SUPPL-5	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208036Orig1s005ltr.pdf
01/03/2017	SUPPL-2	Efficacy-New Dosing Regimen	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208036Orig1s002ltr.pdf

Labels for NDA 208036

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/30/2019	SUPPL-10	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208036s010lbl.pdf
04/07/2017	SUPPL-5	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s005lbl.pdf
02/08/2017	SUPPL-6	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s006lbl.pdf
02/08/2017	SUPPL-6	Labeling-Container/Carton Labels	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s006lbl.pdf
01/03/2017	SUPPL-2	Efficacy-New Dosing Regimen	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s002lbl.pdf
01/11/2016	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208036s000lbl.pdf

Top